These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23369569)

  • 1. Public-private partnerships as driving forces in the quest for innovative medicines.
    Goldman M; Compton C; Mittleman BB
    Clin Transl Med; 2013 Jan; 2(1):2. PubMed ID: 23369569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The innovative medicines initiative: a public private partnership model to foster drug discovery.
    Vaudano E
    Comput Struct Biotechnol J; 2013; 6():e201303017. PubMed ID: 24688725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Innovative Medicines Initiative moves translational immunology forward.
    Goldman M; Wittelsberger A; De Magistris MT
    Eur J Immunol; 2013 Feb; 43(2):298-302. PubMed ID: 23534061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.
    Laverty H; Meulien P
    Front Med (Lausanne); 2019; 6():275. PubMed ID: 31850354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Innovative Medicine Initiative (IMI)].
    Bril A; Canet E
    Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer's disease and other neuropsychiatric disorders.
    North H; Hofmann-Apitius M; Kas MJH; Marston H; Haas M
    Front Neurol; 2023; 14():1174079. PubMed ID: 37521302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rational use of animals in drug development: contribution of the innovative medicines initiative.
    Magda G; Vaudano E; Goldman M
    Altern Lab Anim; 2012 Dec; 40(6):307-12. PubMed ID: 23398335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Innovative Medicines Initiative: Progress to Date.
    Faure JE; Dyląg T; Norstedt I; Matthiessen L
    Pharmaceut Med; 2018; 32(4):243-249. PubMed ID: 30174434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participating in innovative medicines initiative funded neurodegenerative disorder projects-An impact analysis conducted as part of the NEURONET project.
    Hawksworth C; Salih F; Cresswell K; Steukers L; Diaz C; Killin L; Pradier L; Bradshaw A; Dawoud D
    Front Neurol; 2023; 14():1140722. PubMed ID: 37006486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA critical path initiative and its influence on new drug development.
    Woodcock J; Woosley R
    Annu Rev Med; 2008; 59():1-12. PubMed ID: 18186700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks.
    O'Rourke D; Coll-Padrós N; Bradshaw A; Killin L; Pradier L; Georges J; Dawoud DM; Steukers L; Diaz C
    Front Neurol; 2022; 13():994301. PubMed ID: 36408524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery.
    Karawajczyk A; Orrling KM; de Vlieger JS; Rijnders T; Tzalis D
    Front Med (Lausanne); 2016; 3():75. PubMed ID: 28154815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.